We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA will cut funding to some generic drug programs, including generic drug research and information processing modernization, in fiscal 2007 in an effort to shift $52.3 million from existing programs to priority initiatives, including drug safety and influenza pandemic preparedness.
The FDA wants to increase funding for influenza pandemic preparedness efforts, drug safety, the Critical Path Initiative and other priorities in fiscal 2007 by reassigning $52.3 million from various agency programs, according to a high-ranking agency official.
The FDA wants to reassign $52.3 million from various agency programs in fiscal 2007 to help fund influenza pandemic preparedness efforts, drug safety, the Critical Path Initiative and other priorities, according to a high-ranking agency official.
Drug industry officials are awaiting today’s rollout of President Bush’s fiscal 2007 budget blueprint to determine if the industry will bear the costs of a healthcare savings account plan that Bush announced in his State of the Union address.
The House narrowly approved late last week a controversial $40 billion budget reconciliation bill, which includes significant cuts to both Medicaid and Medicare.
President Bush will request more than a two-fold increase in industry R&D tax credits in his fiscal 2007 budget blueprint. But the president’s call to make the credits permanent will likely fail, industry officials say.
Drug industry officials are awaiting President Bush’s fiscal 2007 budget blueprint to determine if the industry will bear the costs of a healthcare savings account plan that Bush is expected to announce in his State of the Union address.
A coalition of Democrats and activist groups are using a recent procedural maneuver as a means to reopen the debate on controversial Medicaid cuts and will target numerous House Republicans that they believe may change their vote, various sources say.
The biotechnology industry is planning to lobby the Bush administration to fund the FDA’s Critical Path Initiative because of concerns that delays in the program could hinder industry’s efforts to develop personalized medicines, a high-ranking industry official says.